Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,600
Employees17,600
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,600
Employees17,600

GILD Key Statistics

Market cap
146.28B
Market cap146.28B
Price-Earnings ratio
23.96
Price-Earnings ratio23.96
Dividend yield
2.61%
Dividend yield2.61%
Average volume
6.58M
Average volume6.58M
High today
$120.28
High today$120.28
Low today
$117.50
Low today$117.50
Open price
$119.77
Open price$119.77
Volume
4.72M
Volume4.72M
52 Week high
$124.61
52 Week high$124.61
52 Week low
$86.08
52 Week low$86.08

GILD News

Simply Wall St 10h
Gilead Sciences: Evaluating Valuation as Shares Trend Higher in 2024

Gilead Sciences (GILD) has seen some movement in its stock price recently, drawing interest from investors tracking the pharmaceutical sector. Shares have climb...

Gilead Sciences: Evaluating Valuation as Shares Trend Higher in 2024
TipRanks 2d
Gilead Sciences’ GS-1219 HIV Study Update: Implications for Investors

Gilead Sciences ((GILD)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!...

Nasdaq 5d
Validea Detailed Fundamental Analysis - GILD

Below is Validea's guru fundamental report for GILEAD SCIENCES, INC. (GILD). Of the 22 guru strategies we follow, GILD rates highest using our P/B Growth Invest...

Validea Detailed Fundamental Analysis - GILD

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

More GILD News

Seeking Alpha 7d
Gilead discontinues early-stage trial for long-acting injectable for HIV

Gilead Sciences (NASDAQ:GILD) has discontinued a Phase 1 trial for GS-1219, a long-acting subcutaneously delivered treatment targeting HIV infections, according...

Gilead discontinues early-stage trial for long-acting injectable for HIV
TipRanks 7d
Gilead terminated Phase 1 study of ‘1219, says RBC Capital

RBC Capital reports that newly updated clinicaltrials.gov records show that Gilead’s (GILD) Phase 1 study testing ‘1219, a next-generation longer-acting injecta...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.